Related Experiment Videos
Summary
Cellular immunity in osteogenic sarcoma patients was assessed using skin-allergic delayed hypersensitivity (RDH) and leucocyte migration inhibition tests (RSLM). RSLM showed potential as a prognostic indicator for tumor growth and disease progression.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Osteogenic sarcoma is a primary bone cancer.
- Cellular immunity plays a role in cancer progression.
- Assessing immune responses can aid in prognosis.
Purpose of the Study:
- To evaluate cell immunity indices in osteogenic sarcoma patients.
- To correlate immune reactions with tumor growth and disease course.
- To investigate the utility of skin-allergic delayed hypersensitivity (RDH) and leucocyte migration inhibition tests (RSLM) in osteogenic sarcoma.
Main Methods:
- Examined 39 osteogenic sarcoma patients prior to treatment.
- Utilized skin-allergic delayed hypersensitivity (RDH) and leucocyte migration inhibition tests (RSLM).
- Employed polysaccharide fractions from osteogenic sarcoma and normal bone as antigens.
Main Results:
- No significant difference in RDH and RSLM reactions between sarcoma and normal bone antigens.
- Negative RSLM correlated with rapid primary tumor growth.
- Positive RSLM and RDH were generally observed in patients with stable disease.
- Negative RSLM and RDH were more frequent in patients with rapidly progressing disease prior to treatment.
Conclusions:
- Leucocyte migration inhibition test (RSLM) shows potential as a prognostic marker in osteogenic sarcoma.
- Immune status, particularly RSLM, may indicate tumor progression.
- RDH and RSLM responses to tumor-specific antigens require further investigation.